Bedoradrine
Ultra-selective long-acting β2-adrenergic receptor agonist that was never marketed
From Wikipedia, the free encyclopedia
Bedoradrine (INN; developmental code names KUR-1246, MN-221) is a sympathomimetic and bronchodilator medication that was developed for the treatment of preterm labor, asthma, and chronic obstructive pulmonary disease (COPD) but was never marketed.[1][2][3] It acts as an ultra-selective long-acting β2-adrenergic receptor agonist.[1][2] The drug was intended for intravenous administration.[1][2]
| Clinical data | |
|---|---|
| Other names | KUR-1246; MN-221 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H32N2O5 |
| Molar mass | 428.529 g·mol−1 |
| 3D model (JSmol) | |
| |
| |